AEON Announces FDA Feedback On ABP-450 Biosimilar Development Following BPD Type 2a Meeting

AEON Biopharma received constructive feedback from the FDA following a Biosimilar BPD Type 2a meeting on its lead investigational asset, signaling a favorable regulatory dialogue that de-risks the development program. The outcome modestly raises the probability of progressing toward a BLA pathway and could move AEON shares by low-single-digit percentages depending on follow-up data and study commitments; next steps will focus on addressing FDA comments and submitting additional data or plans.

Analysis

AEON Biopharma received constructive feedback from the FDA following a Biosimilar BPD Type 2a meeting on its lead investigational asset, signaling a favorable regulatory dialogue that de-risks the development program. The outcome modestly raises the probability of progressing toward a BLA pathway and could move AEON shares by low-single-digit percentages depending on follow-up data and study commitments; next steps will focus on addressing FDA comments and submitting additional data or plans.